-
Nohui health by the domestic "cancer early screening first certificate", the industry into an accelerated period?
Time of Update: 2020-12-14
According to Nohui Health co-founder and CEO Zhu Yeqing, Chang Weiqing after 7 years of research and development, invested more than 100 million U.S. dollars, and completed China's first forward-looking, large-scale, multi-center cancer early screening registered clinical trial "Clear-C", and finally won the first certificate of china's cancer early screening.
-
The European Union will review Merck's lung cancer-targeted drug Tepotinib
Time of Update: 2020-12-14
Tepotinib is designed to treat advanced non-small cell lung cancer (NSCLC) in adults with the interstumin-epithortic conversion factor gene (MET) exon 14 (METex14) jump mutation.
study, the main endpoint was the objective mitigation rate of patients who were followed for at least nine months through an independent review.
-
Gene therapy gives new hope for fighting rare disease DMD? Lilly smashed $135 million into the market
Time of Update: 2020-12-14
Lilly has teamed up with gene editing company Precision BioSciences to unlock the layout of gene therapy for Duchy muscular dystrophy (DMD).
lilly is working with Precision to develop new gene therapies based on its ARCUS technology.
-
JAMA Surg: B colonectomy is used to improve the quality of life of patients with relapse, complexity, or persistent painful diverticulitis
Time of Update: 2020-12-13
study concluded that B colonectomy was better than conservative treatment in improving the quality of life of patients with relapse, complexity or persistent painful diverticulitis, but 10% of patients had severe adverse events after surgery.
-
The first domestically produced APK inhibitor Nsatini was approved
Time of Update: 2020-12-13
According to the official website of the State Drug Administration on November 19 drug approval documents to be received information shows that Beda Pharmaceuticals' ALK inhibitor Nsatinib hydrochlori
-
Cell Metab: Medium GDF-15 reduces vomiting, anorexia, and weight loss caused by platinum chemicals
Time of Update: 2020-12-13
In summary, this article explores the effects of GDF-15 on vomiting, anorexia and weight loss in mice and/or non-human primates caused by platinum chemotherapy, and finds that meso-GDF-15 is a potential treatment that can reduce the side effects of chemotherapy and improve the quality of life of patients.
-
Br J Cancer: Sloan Project UK: 11337 breast catheter in-place cancer (DCIS) screening and pathological characteristics of subsequent events
Time of Update: 2020-12-13
study of the risk of developing the same side breast catheter cancer (left) and indulging cancer (right) each year in patients undergoing breast care surgery (BCS) showed that 7,204 (64%) of the 11,337 patients had high-level DCIS.
-
Cancer Discovery: New Target for Pancreatic Cancer - NetG1
Time of Update: 2020-12-13
NetG1 hyper-expression in CAF was negatively associated with patient survival (Source: Cancer Discovery) In mouse models of pancreatic catheter adenocarcinoma in the body, the researchers observed that knocking out NetG1 in CAF and NTL-1 in tumor cells reduced tumor burden in mice, suggesting that both proteins enhanced tumor development.
-
Cinda Bio published the results of the clinical study of the first-line treatment of liver cancer phase III of the Cindili monoanti-anti-combined beval beval bead mono-anti-first-line
Time of Update: 2020-12-13
study endpoints are OS and progress-free lifetime PFS assessed by the Independent Imaging Review Board (IRRC) based on the RECIST v1.1 standard.
OS and PFS were significantly extended in people treated with first-line liver cancer in China.
-
MIT's annual "50 smart companies" unveiled Baiji, Xinda, Fosun and other companies...
Time of Update: 2020-11-30
6, Fuxing medicine on the list reasons: the first candidate mRNA new crown vaccine product BNT162b2 has been approved by China's State Drug Administration (NMPA) clinical trials.
-
Deqi Pharmaceuticals Hong Kong Stock Exchange is listed with a focus on innovation
Time of Update: 2020-11-30
The funds raised will be used primarily for clinical trials and commercialization of research products, including promoting the marketization of core products ATG-010 in the Asia Pacific region, promoting nine ongoing clinical trials and six preclinical product development studies, enhancing self-development capabilities and enhancing the potential for collaboration with the world's leading pharmaceutical companies.
-
And platinum medicine through the Hong Kong Stock Exchange hearing 4 innovative candidate drugs have entered the clinical stage
Time of Update: 2020-11-30
according to the post-hearing information set, and platinum pharmaceutical fund-raising will be mainly used for the company's core product clinical development, innovative product line promotion and antibody technology platform continued to improve.
FcRn inhibitor Bartoli monoant (HBM9161): a product introduced by And Platinum Pharmaceuticals and enjoying development and commercialization interests in Greater China.
-
BMS Opdivo and Yervoy first-line treatment of malignant thoracic intersessives...
Time of Update: 2020-11-30
On November 23rd, the website of the Drug Review Center (CDE) of the State Drug Administration of China announced that the PD-1 inhibitor Navuliyu monoanti and CTLA-4 antibody Ipimu monoantigen combination therapy with "conditionally approved drugs" would be included in the priority review, and that the adaptation should be developed as: for the treatment of non-removable non-epithelial malignant mammalinoma patients for primary treatment.
-
How come a good anti-cancer drug suddenly doesn't work?
Time of Update: 2020-11-30
effective anti-cancer drugs can work in different ways, killing tumor cells, shrinking and disappearing them, or keeping them under control, preventing them from growing for longer periods of time.
-
JAMA: Challenge the "King of Cancer" survival rate What are the long-term survivors of pancreatic cancer...
Time of Update: 2020-11-30
" Earlier this year, The Lancet-Oncology published a real-world study, Know Your Tumor, led by MD Anderson Cancer Center, which showed that precise treatment based on molecular testing reduced the risk of death in patients with advanced pancreatic cancer by more than half.
-
Well-known pharmaceutical companies will change ownership
Time of Update: 2020-11-30
mentioned Jialin Pharmaceuticals, as a wholly-owned subsidiary of De-Exhibition Health, for many years in the adjustment / blood lipid-lowering drug market ranked as the leading position of domestic drugs, the main product "Al" (common name: Atovastatin calcium tablets) is the first product of the variety through consistent evaluation.
-
Well-known pharmaceutical companies will change ownership
Time of Update: 2020-11-30
mentioned Jialin Pharmaceuticals, as a wholly-owned subsidiary of De-Exhibition Health, for many years in the adjustment / blood lipid-lowering drug market ranked as the leading position of domestic drugs, the main product "Al" (common name: Atovastatin calcium tablets) is the first product of the variety through consistent evaluation.
-
Yingpai Pharmaceutical Baojun: From BD Leader to CEO
Time of Update: 2020-11-30
In October 2018, Yingpai Pharmaceuticals officially announced the appointment of Dr. Bao Jun as CEO, in order to promote the company's domestic and foreign business development, the news came out, causing strong concern in the industry, many people are as curious as I am: what makes this habitual BD master, willing to take on the burden, become a company's helm?
-
China leads the way, and extracellular follicle technology has ushered in a new era of cancer
Time of Update: 2020-11-29
it is understood that as early as 2009, Professor Huang Bo, deputy director of the Institute of Basic Sciences of the Chinese Academy of Medical Sciences, pioneered the organic collection of EVs between 100 and 100 nanometers in size and chemotherapy drugs to form a drug-carrying vesicle treatment tumor technology (Drug-loaded Tumor Microparticle Immunotherapectials, or "DTMI technology") for cancer treatment and to conduct a variety of adaptations and clinical trials in hospitals nationwide.
-
Home-made PD-1 therapy! Baiji Shenzhou Baizean ® (for Reilly zhu single resistance) treatment of non-small cell lung cancer Phase 3 clinical success!
Time of Update: 2020-11-28
November 18, 2020 // -- BeiGene recently announced the evaluation of the anti-PD-1 antibody drug Bazean ® (Tislelizumab, Terelli Phase 3 RATIONALE 303 study (NCT03358875) for the treatment of non-small cell lung cancer (NSCLC) reached the primary endpoint of total lifetime (OS) during the medium-term analysis.
